Filippo Ceccato1, Giorgia Antonelli1, Mattia Barbot1, Marialuisa Zilio1, Linda Mazzai1, Rosalba Gatti1, Martina Zaninotto1, Franco Mantero1, Marco Boscaro1, Mario Plebani2, Carla Scaroni3. 1. Endocrinology UnitDepartment of Medicine DIMED, University-Hospital of Padova, via Ospedale Civile 105, 35128 Padova, ItalyLaboratory Medicine UnitDepartment of Medicine DIMED, University-Hospital of Padova, via Giustiniani 2, 35128, Padova, ItalyEndocrinology UnitUniversity-Hospital of Padova, via Ospedale Civile 105, 35128 Padova, ItalyDepartment of Laboratory Medicine,University-Hospital of Padovavia Giustiniani 2, 35128 Padova, Italy. 2. Endocrinology UnitDepartment of Medicine DIMED, University-Hospital of Padova, via Ospedale Civile 105, 35128 Padova, ItalyLaboratory Medicine UnitDepartment of Medicine DIMED, University-Hospital of Padova, via Giustiniani 2, 35128, Padova, ItalyEndocrinology UnitUniversity-Hospital of Padova, via Ospedale Civile 105, 35128 Padova, ItalyDepartment of Laboratory Medicine,University-Hospital of Padovavia Giustiniani 2, 35128 Padova, ItalyEndocrinology UnitDepartment of Medicine DIMED, University-Hospital of Padova, via Ospedale Civile 105, 35128 Padova, ItalyLaboratory Medicine UnitDepartment of Medicine DIMED, University-Hospital of Padova, via Giustiniani 2, 35128, Padova, ItalyEndocrinology UnitUniversity-Hospital of Padova, via Ospedale Civile 105, 35128 Padova, ItalyDepartment of Laboratory Medicine,University-Hospital of Padovavia Giustiniani 2, 35128 Padova, Italy. 3. Endocrinology UnitDepartment of Medicine DIMED, University-Hospital of Padova, via Ospedale Civile 105, 35128 Padova, ItalyLaboratory Medicine UnitDepartment of Medicine DIMED, University-Hospital of Padova, via Giustiniani 2, 35128, Padova, ItalyEndocrinology UnitUniversity-Hospital of Padova, via Ospedale Civile 105, 35128 Padova, ItalyDepartment of Laboratory Medicine,University-Hospital of Padovavia Giustiniani 2, 35128 Padova, Italy carla.scaroni@unipd.it.
Abstract
OBJECTIVE: The Endocrine Society Clinical Guidelines recommend measuring 24-h urinary free cortisol (UFF) levels using a highly accurate method as one of the first-line screening tests for the diagnosis of Cushing's Syndrome (CS). We evaluated the performance of UFF, urinary free cortisone (UFE), and the UFF:UFE ratio, measured using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. SUBJECTS AND METHODS: The LC-MS/MS was used to analyze UFF and UFE levels in 43 surgically confirmed CS patients: 26 with Cushing's disease (CD, 16 de novo and ten recurrences), 11 with adrenal CS and six with ectopic CS; 22 CD patients in remission; 14 eu-cortisolemic CD patients receiving medical therapy; 60 non-CS patients; and 70 healthy controls. Sensitivity and specificity were determined in the combined groups of non-CS patients, healthy controls, and CD in remission. RESULTS: UFF>170 nmol/24 h showed 98.7% specificity and 100% sensitivity for de novo CS, while sensitivity was 80% for recurrent CD patients, who were characterized by lower UFF levels. The UFF:UFE and UFF+UFE showed lower sensitivity and specificity than UFF. Ectopic CS patients had the highest UFF and UFF:UFE levels, which were normal in the CD remission patients and in those receiving medical therapy. CONCLUSIONS: Our data suggest high diagnostic performance of UFF excretion measured using LC-MS/MS, in detecting de novo CS. UFF:UFE and UFF+UFE assessments are not useful in the first step of CS diagnosis, although high levels were found to be indicative of ectopic CS.
OBJECTIVE: The Endocrine Society Clinical Guidelines recommend measuring 24-h urinary free cortisol (UFF) levels using a highly accurate method as one of the first-line screening tests for the diagnosis of Cushing's Syndrome (CS). We evaluated the performance of UFF, urinary free cortisone (UFE), and the UFF:UFE ratio, measured using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. SUBJECTS AND METHODS: The LC-MS/MS was used to analyze UFF and UFE levels in 43 surgically confirmed CS patients: 26 with Cushing's disease (CD, 16 de novo and ten recurrences), 11 with adrenal CS and six with ectopic CS; 22 CDpatients in remission; 14 eu-cortisolemic CDpatients receiving medical therapy; 60 non-CS patients; and 70 healthy controls. Sensitivity and specificity were determined in the combined groups of non-CS patients, healthy controls, and CD in remission. RESULTS:UFF>170 nmol/24 h showed 98.7% specificity and 100% sensitivity for de novo CS, while sensitivity was 80% for recurrent CDpatients, who were characterized by lower UFF levels. The UFF:UFE and UFF+UFE showed lower sensitivity and specificity than UFF. Ectopic CS patients had the highest UFF and UFF:UFE levels, which were normal in the CD remission patients and in those receiving medical therapy. CONCLUSIONS: Our data suggest high diagnostic performance of UFF excretion measured using LC-MS/MS, in detecting de novo CS. UFF:UFE and UFF+UFE assessments are not useful in the first step of CS diagnosis, although high levels were found to be indicative of ectopic CS.
Authors: F Ceccato; G Antonelli; A C Frigo; D Regazzo; M Plebani; M Boscaro; C Scaroni Journal: J Endocrinol Invest Date: 2017-02-28 Impact factor: 4.256
Authors: Marta Araujo-Castro; Pablo Valderrábano; Héctor F Escobar-Morreale; Felicia A Hanzu; Gregori Casals Journal: Endocrine Date: 2020-11-21 Impact factor: 3.633
Authors: G Aranda; M Careaga; F A Hanzu; I Patrascioiu; P Ríos; M Mora; B Morales-Romero; W Jiménez; I Halperin; G Casals Journal: Pituitary Date: 2016-10 Impact factor: 4.107